ACAD - ACADIA Pharmaceuticals Inc.
Pre-Market:
Chart Events
Williams %R
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 23.50 |
| Open | 23.11 |
| Bid | 22.52 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 22.35 - 23.94 |
| 52 Week Range | 12.24 - 26.04 |
| Volume | |
| Avg. Volume | 1,605,450 |
| Market Cap | 3.887B |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.92 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.16 |
Fair Value
Related Research
Business WireAcadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
SAN DIEGO, June 01, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023 at 10:00 a.m. Eastern Time in New York, NY.
ZacksAcadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of -28.57% and 2.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireAcadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
SAN DIEGO, May 08, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2023.
Simply Wall St.ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Is Matching Sentiment Around Its Revenues
You may think that with a price-to-sales (or "P/S") ratio of 6.9x ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) is a...
Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 05, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 24, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 98,850 shares of common stock and 59,934 restricted stock units ("RSUs") to 44 new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee of Acadia’s Board of Directors approved the awards as an inducement material to the new employees
Business WireAcadia Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, May 02, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
Business WireAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
SAN DIEGO, April 25, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Monday, May 8, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Business WireAcadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
SAN DIEGO, April 20, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that four posters in Rett syndrome will be presented at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Mass.
Business WireAcadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
SAN DIEGO, April 17, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that DAYBUE™ (trofinetide) is now available for the treatment of Rett syndrome in adult and pediatric patients two years of age and older in the United States. DAYBUE has demonstrated the potential to improve the signs and symptoms of Rett syndrome. DAYBUE was approved by the U.S. Food and Drug Administration (FDA) on March 10, 2023, and is the first and only drug approved by the FDA for the treatment of Rett s
Business WireAcadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 11, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 22nd Annual Needham Virtual Healthcare conference on Tuesday, April 18, 2023 at 1:30 p.m. Eastern Time.
- Simply Wall St.
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Shift From Loss To Profit
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) is possibly approaching a major achievement in its business, so we would...
BenzingaAcadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment
The FDA has approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older. Daybue is the first and only drug approved for treating Rett syndrome, a rare genetic neurological and developmental disorder that causes a progressive loss of motor skills and language. Rett syndrome primarily affects females. Rett syndrome is believed to affect 6,000 to 9,000 patients in the U.S., with a diagnosed population of appr
MarketWatchAcadia’s rare-disease drug to cost $575,000 to $595,000
Acadia Pharmaceuticals Inc. (ACAD) said its newly approved treatment for Rett syndrome has an annual list price ranging from $575,000 to $595,000, according to a company spokesperson. The Food and Drug Administration on Friday approved Daybue, the first therapy to treat Rett syndrome, a rare disease that has been diagnosed in 4,500 adults and children in the U.S. The company said it expects to have the drug available in the U.S. by the end of April.
Business WireAcadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
SAN DIEGO, March 11, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the first and only drug approved for the treatment of Rett syndrome.
Motley Fool1 Top Biotech Stock to Buy in March
Biotech stocks had a rough 2022. Concerns about a stricter Food and Drug Administration (FDA), rising interest rates, and a growing aversion to risk weighed particularly heavily on clinical and early commercial-stage biotech stocks. The silver lining, if you can call it that, is that the small-to-mid-cap biotech landscape is now chock-full of companies trading at a steep discount relative to their long-term value proposition.
Insider MonkeyACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2022 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Good day, ladies and gentlemen. And welcome to ACADIA Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Gigi, and I will be your coordinator for today. At this time, all participants are in listen-only mode. We […]
- Simply Wall St.
ACADIA Pharmaceuticals Full Year 2022 Earnings: EPS Misses Expectations
ACADIA Pharmaceuticals ( NASDAQ:ACAD ) Full Year 2022 Results Key Financial Results Revenue: US$517.2m (up 6.8% from FY...
BenzingaAnalysts See Steady Growth For Acadia Pharma's Nuplazid
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) reported a Q4 EPS loss of $(0.26), missing the consensus of $(0.24) and sales of $136.49 million, beating the consensus of $134.07 million. For FY23, the company expects Nuplazid sales of $520-$550 million compared to a consensus of $569.16 million. Raymond James, maintaining a Market Perform rating, writes that 2023 revenue guidance does not include potential contributions from trofinetide, with a PDUFA date of March 12 for Rett Syndrome. The analyst pr
- Thomson Reuters StreetEvents
Q4 2022 ACADIA Pharmaceuticals Inc Earnings Call
Q4 2022 ACADIA Pharmaceuticals Inc Earnings Call
ZacksAcadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of -4% and 1.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
SAN DIEGO, February 27, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2022.
ZacksAcadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireAcadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
SAN DIEGO, February 14, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2022 financial results on Monday, February 27, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 27, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Business WireAcadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
SAN DIEGO, January 09, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. Williamson will lead research and development at Acadia and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, Chief Executive Officer of Acadia. Dr. Williamson will succeed Dr. Srdjan Stankovic, whose planned retirement was announced last year.
- Simply Wall St.
Investors in ACADIA Pharmaceuticals (NASDAQ:ACAD) from three years ago are still down 62%, even after 4.1% gain this past week
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
